Ukraine National Academy of Science Wins DeNovix Pink Spectrophotometer / Fluorometer


DeNovix Inc is proud to announce the winner of a Special Edition Pink DS-11 FX+ Spectrophotometer/Fluorometer. The winner, randomly chosen from thousands of eligible entries to the company’s drawing, is Dr Olena Livinska of the National Academy of Science of Ukraine. Olena is a research associate in the Department of Physiology of Industrial Microorganisms in the Zabolotny Institute of Microbiology and Virology. Olena is also the Head of Council of Young Researchers (CYR) in the Institute.


Dr Livinska stated: “As a part of CYR I am especially happy to emphasise the importance of this prize for our young team of researchers. Our country is going through hard times with science funding decreased severely. Nevertheless, young researchers are still inspired and try to do their best. They continue their research and work as volunteers for the popularisation of science. I am proud to work with these people and feel grateful to DeNovix and Biolabtech for an opportunity to make my contribution.”


The DS-11 FX+, recently named Reviewers’ Choice Best Life Science Product 2017, is a stand-alone instrument for rapid UV-Vis and fluorometric quantification of biomolecules. The primary application


Dr Olena Livinska


is for quantification of 1uL samples of nucleic acids and proteins. Other applications include analysis of fluorescently labelled biomolecules, kinetic studies, and microbial cell quantification.


“Our team spoke with Olena the morning after she learned about being drawn as the winner. At DeNovix, we thought that the Pink FX+ was something unique that researchers would be excited about. But more than that, we hoped the winner would be a person who would really put the system to work. Olena was so thankful and excited. We know the instrument will expand the research abilities for her and the dozens of young scientists she’s working with in Kiev,” said Kevin Kelley,


Business Director at DeNovix.


Scientists around the world gained entries to the contest by visiting a DeNovix product page, watching videos, visiting the DeNovix Facebook page, sharing the contest with colleagues, etc.


Olena’s winning entry was generated from a visit to the DeNovix Facebook page.


42445pr@reply-direct.com


Harvesting Penicillin from Yeast Cells


“The rise of drug-resistant superbugs has brought a real urgency to our search for new antibiotics. Our experiments show that yeast can be engineered to produce a well-known antibiotic. This opens up the possibility of using yeast to explore the largely untapped treasure trove of compounds in the nonribosomal peptide family to develop a new generation of antibiotics and anti-inflammatories.”


Dr Tom Ellis Dr Ali Awan


Scientists from Imperial College London (ICL) have successfully inserted fungus genes into a yeast cell to make it produce penicillin molecules. In this early stage research* the synthetic biologists found that the re-engineered yeast, which manufactured the nonribosomal peptide antibiotic penicillin, displayed antibacterial properties against streptococcus bacteria when tested under laboratory conditions.


Dr Tom Ellis, from the Centre for Synthetic Biology at Imperial College London, explained: “Humans have been experimenting with yeast for thousands of years. From brewing beer to getting our bread to rise and more recently for making compounds like anti-malarial drugs, yeast is the microscopic workhorse behind many processes.


Dr Ali Awan, co-author from the Department of Bioengineering at Imperial College London, explained: “Fungi have had millions of years to evolve the capability to produce bacteria-killing penicillin. We scientists have only been working with yeast in this context for a handful of years, but now that we’ve developed the blueprint for coaxing yeast to make penicillin, we are confident we can further refine this method to create novel drugs in the future.


“We believe yeast could be the new mini-factories of the future, helping us to experiment with new compounds in the nonribosomal peptide family to develop drugs that counter antimicrobial resistance.”


The team are currently looking for fresh sources of funding and new industrial collaborators to take their research to the next level.


The research was carried out in conjunction with SynbiCITE, which is the UK’s national centre for the commercialisation of synthetic biology.


*Published in Nature Communications 42683pr@reply-direct.com SEND ALL YOUR RESEARCH AND EVENTS NEWS STORIES TO HEATHER@INTLABMATE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154  |  Page 155  |  Page 156  |  Page 157  |  Page 158  |  Page 159  |  Page 160  |  Page 161  |  Page 162  |  Page 163  |  Page 164  |  Page 165  |  Page 166  |  Page 167  |  Page 168  |  Page 169  |  Page 170  |  Page 171  |  Page 172